Clinical Trials Sponsored by Cancer Prevention and Research Institute, Italy

Total 2430 results

H. Lee Moffitt Cancer Center and Research Institute
American Cancer Society, Inc.

Terminated

Evaluation of Image-guided Brushing of Pancreatic Cyst Wall in Diagnosis of Cystic Pancreatic Tumors

Pancreatic Tumors

United States
H. Lee Moffitt Cancer Center and Research Institute
Vaccinex Inc.

Recruiting

Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer

HER2-positive Breast Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals

Recruiting

Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

Myelodysplastic Syndromes

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals

Active, not recruiting

Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma

Melanoma | Unresectable Melanoma | Advanced Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Regeneron Pharmaceuticals

Active, not recruiting

Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer

Hormone Receptor-positive Breast Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
ModernaTX, Inc.

Completed

COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients

Covid19 | SARS-CoV2 Infection

United States
H. Lee Moffitt Cancer Center and Research Institute
Array BioPharma

Completed

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

Non-Small Cell Lung Cancer | Lung Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Regeneron Pharmaceuticals

Terminated

Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC

Cutaneous Squamous Cell Carcinoma of the Head and Neck | Cutaneous Squamous Cell Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals

Completed

Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)

Multiple Myeloma

United States
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation

Completed

A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib

Myelomonocytic Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Olympus Corporation

Completed

Novel Exoscope System for 5-ALA Fluorescence-Guided Surgery for Gliomas

Glioma | Brain Tumor

United States
H. Lee Moffitt Cancer Center and Research Institute
Aprea Therapeutics

Completed

Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm

United States
Eleos, Inc.
H. Lee Moffitt Cancer Center and Research Institute

Terminated

A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

United States
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.

Completed

Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer

Breast Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation

Completed

Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients

Chronic Phase Chronic Myeloid Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals

Completed

SOM 230 and Gemcitabine in Advanced Pancreatic Cancer

Pancreatic Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis; Amgen

Withdrawn

Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat

Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Seagen Inc.

Terminated

Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30

Peripheral T-Cell Lymphoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Celgene Corporation

Completed

Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab

Mantle Cell Lymphoma | Lymphocytic Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
BeiGene, Ltd.

Recruiting

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

Follicular Lymphoma | Marginal Zone Lymphoma | B-Cell Lymphoma

United States
Vivent Health
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

The Prevalence of Oral HPV Infection and Oral Lesions in People Living With HIV (SWISH)

Human Immunodeficiency Virus | Human Papilloma Virus

United States
H. Lee Moffitt Cancer Center and Research Institute
Precigen, Inc

Recruiting

Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies

Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Triple Negative Breast Cancer Malignancies

United States
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.

Recruiting

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

Advanced Basal Cell Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Jazz Pharmaceuticals

Recruiting

CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML

Acute Myeloid Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Viewray Inc.

Recruiting

Habitat Escalated Adaptive Therapy (HEAT), With Neoadjuvant Radiation for Soft Tissue Sarcoma

High Grade Sarcoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Jazz Pharmaceuticals

Recruiting

Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML

Acute Myeloid Leukemia With FLT3/ITD Mutation

United States
H. Lee Moffitt Cancer Center and Research Institute
Clinigen, Inc.

Recruiting

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Melanoma Stage IV | Melanoma Stage III | Inoperable Disease

United States
DNAtrix, Inc.
H. Lee Moffitt Cancer Center and Research Institute

Suspended

DNX-2440 for Resectable Colorectal Liver Metastasis

Melanoma | Sarcoma | Breast Cancer | Gastric Cancer | Colorectal Cancer | Gastrointestinal Stromal Tumors | Periampullary Cancer | Liver Metastases | Renal Cell Cancer | Liver Metastasis Colon Cancer | Squamous Cell Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Jazz Pharmaceuticals

Completed

Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Relapsed Acute Lymphoblastic Leukemia | Lymphoid Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation

Active, not recruiting

Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion

Leukemia | Chronic Myelomonocytic Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Elucent Medical

Completed

Evaluation of EnVisio SmartClip for Intraoperative Localization of Breast Masses

Breast Cancer

United States
Incyte Corporation
H. Lee Moffitt Cancer Center and Research Institute

No longer available

Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer
H. Lee Moffitt Cancer Center and Research Institute
Celgene Corporation

Completed

Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS

Myelodysplastic Syndrome | MDS

United States
H. Lee Moffitt Cancer Center and Research Institute
Celgene Corporation

Completed

Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer

Bladder Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.

Terminated

Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)

Mesothelioma

United States
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.

Terminated

Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors

Pancreatic Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
ESP Pharma

Terminated

Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation

Acute Myeloid Leukemia (AML)

United States
H. Lee Moffitt Cancer Center and Research Institute
Schering-Plough

Terminated

Phase I Study of Temozolomide, Valproic Acid and Radiation Therapy in Patients With Brain Metastases

Brain Metastases

United States
H. Lee Moffitt Cancer Center and Research Institute
Endo Pharmaceuticals

Completed

Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals

Terminated

Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

Non-Hodgkin's Lymphoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Aventis Pharmaceuticals

Terminated

Pharmacogenomic Study of Docetaxel and Cisplatin, Followed by Docetaxel, Cisplatin and Irradiation.

Esophageal Adenocarcinomas | Adenocarcinomas of the Gastroesophageal Junction

United States
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.

Completed

Erlotinib Study for Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.

Completed

A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer

Metastatic Pancreatic Carcinoma

United States
National Institute of Neurological Disorders and...
Harborview Injury Prevention and Research Center

Completed

Phase III Double Blind Trial of Valproate Sodium for Prophylaxis of Post Traumatic Seizures

Post-Traumatic Seizure Disorder | Head Injuries
H. Lee Moffitt Cancer Center and Research Institute
James and Esther King Biomedical Research Program

Recruiting

Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers

Lung Diseases | Lung Cancer, Protection Against

United States
H. Lee Moffitt Cancer Center and Research Institute
James and Esther King Biomedical Research Program

Completed

Biobank for African American Prostate Cancer Research in Florida

Prostate Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
James and Esther King Biomedical Research Program

Completed

Capitalizing on a Teachable Moment to Promote Smoking Cessation

Smoking Cessation

United States
H. Lee Moffitt Cancer Center and Research Institute
James and Esther King Biomedical Research Program

Recruiting

Enhancing Long-Term Smoking Abstinence Among Cervical Cancer Survivors (Project ACCESS)

Smoking Cessation | Cervical Cancer | High Grade Cervical Dysplasia

United States
H. Lee Moffitt Cancer Center and Research Institute
James and Esther King Biomedical Research Program

Completed

Facilitating Smoking Cessation With Reduced Nicotine Cigarettes

Smoking Cessation

United States
Shanghai Institute Of Biological Products
Henan Center for Disease Control and Prevention

Unknown

A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza Vaccine

H7N9 Influenza

China

Clinical Trials Sponsored by Cancer Prevention and Research Institute, Italy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations